GlaxoSmithKline (GSK) has partnered with Angiochem to discover, develop and commercialise drugs for lysosomal storage diseases. The deal is potentially worth more than US$300 M to Angiochem, including up to US$31.5 M in upfront cash, research funding and other fees if GSK accesses the targets available to the collaboration. Unlike currently marketed enzyme replacement therapies, Angiochem’s engineered peptide compound (EPiC) enzyme therapeutics are designed to penetrate the blood-brain barrier and thus restore enzyme function in the CNS.